RenovoRxRNXT
RNXT
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
38% more funds holding
Funds holding: 13 [Q3] → 18 (+5) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
3.66% less ownership
Funds ownership: 7.88% [Q3] → 4.22% (-3.66%) [Q4]
35% less capital invested
Capital invested by funds: $2M [Q3] → $1.31M (-$695K) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$3
240%
upside
Avg. target
$3
240%
upside
High target
$3
240%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth 17% 1-year accuracy 33 / 197 met price target | 240%upside $3 | Buy Reiterated | 4 Apr 2025 |
Financial journalist opinion
Based on 6 articles about RNXT published over the past 30 days
Neutral
Business Wire
2 days ago
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will present at the LD Micro Invitational XV: New York 2025 conference taking place at the Westin Grand Central Hotel, New York, NY on April 10, 2025. Mr. Bagai will discuss recent corporate m.
Neutral
Business Wire
5 days ago
RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced its financial results and business updates for the fourth quarter and full year ended December 31, 2024. “The fourth quarter of 2024 marks a significant milestone in our company history as we have generated our first revenue from sa.
Neutral
Business Wire
1 week ago
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, announced today that a new human pharmacokinetic (PK) data abstract was presented at the Society of Surgical Oncology (SSO) 2025 Annual Meeting on March 27 – 29, 2025 in Tampa, FL: ePoster P379. The abstract provides new human PK data relevant to R.
Neutral
Business Wire
1 week ago
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, is proud to announce that a publication supporting the Company's proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform for targeted locoregional drug delivery will be recognized in the Journal of Vascular and Interventional Radiology (.
Neutral
Business Wire
2 weeks ago
RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced that it will host a fireside chat with Shaun Bagai, Chief Executive Officer, on Thursday, April 3, 2025, at 12:00 p.m. ET. Mr. Bagai will discuss RenovoRx's continued momentum of its RenovoCath commercial efforts, including new purch.
Neutral
Business Wire
2 weeks ago
RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, is proud to announce a presentation of a new pre-clinical clinical data abstract at the upcoming Society of Surgical Oncology (SSO) 2025 Annual Meeting. The abstract, titled “Pharmacodynamics of Intra-arterial vs. Intravenous Gemcitabine in Locally.
Neutral
Business Wire
1 month ago
RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced continuing momentum with the Company's RenovoCath commercial strategy, with new purchase orders received from several esteemed, high volume National Cancer Institute-designated centers. Additionally, RenovoRx reported that utilization of.
Neutral
Business Wire
1 month ago
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, an innovative, FDA-cleared device, highlighted its recent abstract presentation at the 2025 Society of Interventional Oncology Annual Conference (“SIO 2025”) in Las Vegas, Nevada. The abstract published promising pre-clinical data from the use of RenovoRx's patented Trans-Arterial Micro-Perfusion.
Neutral
Business Wire
1 month ago
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, an innovative, FDA-cleared delivery platform, today announced the closing of its previously announced $12.1 million firm commitment underwritten public offering of common stock led by multiple fundamental healthcare institutional investors. “We are very excited to close this common stock-only fi.
Neutral
Business Wire
1 month ago
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced the pricing of a firm commitment, underwritten public offering of 11,523,810 shares of its common stock at a price to the public of $1.05 per share. All shares in the offering are being sold by RenovoRx. The gross proceeds from the offering.
Charts implemented using Lightweight Charts™